We Can Edit Your Genes Now. Almost Nobody Can Afford It.

In December 2023, the FDA approved Casgevy — the first CRISPR-based gene therapy — for sickle cell disease. It was, by any measure, a scientific revolution delivered in a syringe. A one-time treatment that edits your own stem cells to produce functional hemoglobin, potentially curing a disease that has tortured millions for millennia.

Fifteen months later, approximately 90 patients have had their cells collected to begin the treatment process. Not 90,000. Not 9,000. Ninety.

There are roughly 100,000 Americans living with sickle cell disease. Globally, 20 million. The gap between "we can cure this" and "we are curing this" is a canyon — and it tells us more about the future of medicine than any breakthrough paper ever will.

The Price Tag Breakdown

Casgevy's list price is $2.2 million. But that's just the therapy itself. The full cost of treatment — including hospitalization, chemotherapy conditioning (busulfan myeloablation to clear existing bone marrow), multiple apheresis sessions, months of recovery monitoring, and travel — pushes the total to $2.5–3.5 million per patient.

Gene Therapy	Condition	List Price	Year Approved
Hemgenix	Hemophilia B	$3,500,000	2022
Lyfgenia	Sickle Cell Disease	$3,100,000	2023
Roctavian	Hemophilia A	$2,900,000	2023
Casgevy	Sickle Cell / Beta Thalassemia	$2,200,000	2023
Zolgensma	Spinal Muscular Atrophy	$2,125,000	2019
Elevidys	Duchenne Muscular Dystrophy	$3,200,000	2023

For context: the average American household earns $80,610 per year. Casgevy costs 27 years of median household income. Hemgenix costs 43.

The Manufacturing Bottleneck Nobody Talks About

The price isn't pure greed — though margins are generous. The fundamental problem is that each Casgevy dose is manufactured from the patient's own cells. This is autologous cell therapy: your blood is drawn, your stem cells are extracted via apheresis (sometimes requiring multiple sessions), shipped to a manufacturing facility, gene-edited with CRISPR-Cas9, quality-tested, and shipped back.

This process takes months. Vertex CEO Reshma Kewalramani was blunt about it at the Bernstein conference: "It is a long patient journey, and even Vertex cannot make that patient journey shorter."

As of Q1 2025, Vertex has activated roughly 65 authorized treatment centers (ATCs) globally, nearing their target of 75. In the US, 48 sites are operational. For patients in rural areas — where sickle cell disease is concentrated in the South — the nearest center may be a plane flight away.

"Unfortunately, especially, our sickle cell disease patients are very sick. There are patients who might want to start the journey, get the referral to transplant, and then die." — Reshma Kewalramani, CEO, Vertex Pharmaceuticals

The Durability Case Is Real

The clinical data, at least, is genuinely remarkable. Longer-term follow-up presented at the 2025 European Hematology Association congress shows:

Metric	Sickle Cell (SCD)	Beta Thalassemia (TDT)
Evaluable patients meeting primary endpoint	95.6% (43/45)	98.2% (54/55)
Mean VOC-free / transfusion-free duration	35.0 months	40.5 months
Longest follow-up	5.5+ years	6+ years
Stable fetal hemoglobin levels	✅ Yes	✅ Yes
Iron removal therapy stopped (TDT)	—	69.6% (39/56)

This is real durability. Not "symptoms managed" — functionally cured. Sickle cell patients who haven't had a pain crisis in over five years. Thalassemia patients who haven't needed a blood transfusion in six. The allelic editing remains stable. It works.

The Access Arithmetic

Here is where the math gets uncomfortable:

Metric	Value
Americans with SCD	~100,000
Eligible for Casgevy (age 12+, HbSS/Sβ⁰, documented VOCs)	~20,000–30,000
Patients with cells collected (as of Q1 2025)	~90
Authorized treatment centers (US)	48
Treatment cost per patient (total)	$2.5–3.5M
Annual cost of SCD management per patient	$42,000–$250,000
FDA-approved cell & gene therapies (total)	46
Global gene therapy market (2024)	$5.1 billion
Projected market (2030)	$15.85 billion (20.8% CAGR)

At the current rate — roughly 90 patients initiated in 15 months — it would take over 400 years to treat just the eligible US sickle cell population. Even if throughput triples, you're looking at over a century.

The cost-effectiveness argument is real: a patient with severe SCD costs the healthcare system $42,000–$250,000 per year in hospitalizations, transfusions, and emergency visits. Over a lifetime (average life expectancy with SCD: ~54 years), that's $2–$13 million. A one-time $2.2 million cure could be a bargain — but only if payors actually pay, and patients can actually reach a treatment center.

The Graveyard of Withdrawn Therapies

Gene therapy's economics have already killed products. Bluebird Bio withdrew its gene therapies Skysona and Zynteglo from the European market in 2021–2022, unable to negotiate reimbursement with national health systems. The company's US sickle cell therapy Lyfgenia ($3.1M) launched alongside Casgevy and has struggled for uptake. In February 2025, bluebird bio was acquired by a larger firm after its stock collapsed 95% from its peak.

The pattern: brilliant science → astronomical price → slow uptake → commercial failure → withdrawal. The therapies work. The business model doesn't.

What Bends the Curve

Three things could change this:

1. In vivo gene editing. Casgevy is ex vivo — cells extracted, edited, returned. The next generation is in vivo: injecting the CRISPR machinery directly into the patient's body. Intellia Therapeutics' NTLA-2001 (for ATTR amyloidosis) and Verve Therapeutics' VERVE-102 (for high cholesterol) are in clinical trials for direct, one-shot delivery. If this works, it kills the manufacturing bottleneck entirely — no apheresis, no cell processing facility, no months of waiting. A single infusion in a doctor's office.

2. Outcomes-based pricing. Vertex is negotiating payment structures where the full fee is only collected if the therapy works over multiple years. If the cure fails, payments stop. This shifts risk from payors to manufacturers and could unlock insurance coverage for therapies that currently get denied.

3. Manufacturing scale. The global cell and gene therapy manufacturing capacity is expanding — new facilities from Lonza, Catalent, Samsung Biologics, and dozens of CDMOs. As batch sizes increase and automation improves, per-dose costs should decline. But "should" has been doing a lot of work in gene therapy economics for a decade.

Sources & References

1. FDA Approves Casgevy, the First CRISPR Therapy, for Sickle Cell Disease — GEN, December 2023. FDA approval of Casgevy (exagamglogene autotemcel) for SCD.
2. Casgevy priced at $2.2 million — BioPharma Dive. Vertex/CRISPR Therapeutics pricing announcement.
3. Vertex, CRISPR Set Lofty Goal for Casgevy as Patient Starts Ramp — BioSpace. ~90 patients with cells collected as of Q1 2025; Reshma Kewalramani quotes from Bernstein 41st Annual Strategic Decisions Conference; 65 ATCs activated, 48 US.
4. Time and Distance: Vertex Tackles CASGEVY Access Challenges — BioProcess International. Kewalramani quote on patient mortality during treatment journey.
5. Vertex Reports Long-Term Results for Casgevy in Sickle Cell and Thalassemia — Clinical Trials Arena. EHA 2024 data: 95.6% SCD, 98.2% TDT primary endpoint, durability data.
6. Vertex Presents Longer-Term Data Showing Durability of Casgevy — Fierce Pharma. Extended follow-up (5.5+ years SCD, 6+ years TDT), stable fetal hemoglobin.
7. FDA Approves $3.5 Million Hemophilia B Gene Therapy — Pharmaceutical Technology. Hemgenix (CSL/uniQure) approval and pricing, November 2022.
8. Novartis' SMA Gene Therapy Approved by FDA at $2.125 Million — BioSpace. Zolgensma approval and pricing, May 2019.
9. Sarepta's Duchenne Gene Therapy Elevidys Priced at $3.2 Million — BioPharma Dive. Elevidys approval and pricing, June 2023.
10. FDA Approves $2.9 Million Gene Therapy for Hemophilia A — Managed Healthcare Executive. Roctavian (BioMarin) approval and pricing.
11. Zynteglo — European Medicines Agency — EMA. Marketing authorisation withdrawal at request of bluebird bio, March 2022.
12. Bluebird Bio Withdraws Gene Therapies from Europe — BioPharma Dive. Skysona and Zynteglo withdrawal, inability to negotiate EU reimbursement.
13. FDA Designates Intellia's Nexiguran Ziclumeran (nex-z) as RMAT — Goodwin Law, December 2024. NTLA-2001 for ATTR amyloidosis, in vivo CRISPR gene editing.
14. Verve Therapeutics' VERVE-102 Reduces LDL-C in HEART-2 Trial — CGT Live. In vivo base editing for PCSK9, Phase 1b clinical data (NCT06164730).
15. Gene Therapy Market Size, Share & Trends Report, 2030 — Grand View Research. Global gene therapy market projections.
16. Costs and Impact of Disease in Adults with Sickle Cell Disease — Blood Advances, ASH. Annual per-patient SCD costs: $14,012–$80,842; total direct medical costs ~$44,160/year.
17. Gene Therapy in 2024: Persistent Approvals — Precision Medicine Online. 40+ FDA-approved cell and gene therapies as of late 2024.